Moderate

Transfusional iron overload & chelation

iron overload · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Repeated red cell transfusion deposits iron in the heart, liver and endocrine organs because humans cannot excrete excess iron. Chelation therapy prevents organ damage in chronically transfused patients such as those with thalassaemia, sickle cell disease and myelodysplasia.

Red flags

  • Cardiac iron overload with arrhythmia or heart failure
  • Agranulocytosis/neutropenia on deferiprone
  • Rising creatinine on deferasirox
  • New diabetes or hypothyroidism
  • GI bleeding on deferasirox

Assessment

Differential diagnosis

  • Hereditary haemochromatosis
  • Other secondary iron overload (dyserythropoiesis)
  • Chronic liver disease
  • Hyperferritinaemia of inflammation
  • Non-alcoholic fatty liver disease

Investigations

  • Serum ferritin trend
  • Transferrin saturation
  • Liver iron concentration by MRI (R2/R2*)
  • Cardiac iron by T2* MRI
  • LFTs and endocrine screen (glucose, thyroid, gonadal)
  • Transfusion history and cumulative units

Management

  • Identify chronically transfused patients at risk (roughly after 10-20 units or ferritin rising above ~1000 mcg/L)
  • Quantify iron burden with ferritin trend and cardiac/hepatic MRI rather than ferritin alone
  • Select a chelator by iron distribution, adherence and tolerance
  • Start oral deferasirox or deferiprone, or subcutaneous desferrioxamine
  • Intensify chelation (often combination) when cardiac iron is high
  • Monitor efficacy with serial ferritin and MRI and adjust dose
  • Monitor for toxicity: renal/hepatic (deferasirox), agranulocytosis (deferiprone), ocular/auditory/growth (desferrioxamine)
  • Check weekly FBC on deferiprone for neutropenia/agranulocytosis
  • Manage established endocrine, cardiac and hepatic complications
  • In suitable MDS/non-anaemic contexts, consider venesection as an alternative to chelation

Drugs & doses

Deferasirox 14-28 mg/kg PO once daily (film-coated tablet), titrate to iron burden
Deferiprone 75-100 mg/kg/day PO in 3 divided doses
Desferrioxamine 20-40 mg/kg SC infusion over 8-12 h, 5-7 nights/week
Combination deferiprone + desferrioxamine for severe cardiac loading

Disposition

Specialist haematology clinic; multidisciplinary surveillance with cardiology and endocrinology; regular MRI monitoring.

Complications & pitfalls

  • Iron-overload cardiomyopathy and arrhythmia
  • Hepatic fibrosis/cirrhosis
  • Endocrinopathy (diabetes, hypogonadism, hypothyroidism)
  • Chelator toxicity (renal, agranulocytosis, ocular/auditory)
  • Growth impairment in children on desferrioxamine

Exam pearls

  • Cardiac T2* MRI detects dangerous iron loading before symptoms
  • Deferiprone has the best cardiac iron removal but needs weekly FBC monitoring
  • Ferritin alone underestimates cardiac risk - image the heart
  • Combination chelation is used for severe cardiac loading
  • Adherence is the main determinant of outcome

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.